Bengaluru's Tricog Health Targets 10 Crore Cardiac Screenings by 2030
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Early detection through low-cost AI screenings can prevent emergency heart surgeries that typically cost ₹3,00,000 to ₹8,00,000.
- Increased availability of tech-enabled ECGs in small clinics reduces the need for expensive travel to specialized city hospitals.
- Proactive cardiac health management can help you maintain a 'No Claim Bonus' on your health insurance, keeping your premiums lower over time.
Bengaluru-based healthtech firm Tricog Health aims to conduct 100 million (10 crore) cardiac screenings by 2030, leveraging its AI-enabled ECG devices and specialist reviews. Since its inception in 2014, the company has already screened over 41 million patients across India and 14 other countries. This ambitious goal is set to significantly improve early detection and reduce diagnosis delays for cardiovascular diseases.
- ▸Tricog Health aims to screen 10 crore patients for heart conditions by 2030.
- ▸The company uses AI-enabled ECG devices complemented by specialist doctor reviews for accurate diagnosis.
- ▸This initiative is designed to reduce diagnosis delays and boost early detection of cardiovascular diseases.
- ▸Tricog Health, founded in 2014, has already screened over 41 million patients across India and 14 countries.
- ✓Tricog Health aims to screen 10 crore patients for heart conditions by 2030.
- ✓The company uses AI-enabled ECG devices complemented by specialist doctor reviews for accurate diagnosis.
- ✓This initiative is designed to reduce diagnosis delays and boost early detection of cardiovascular diseases.
- ✓Tricog Health, founded in 2014, has already screened over 41 million patients across India and 14 countries.
Bengaluru-based healthtech pioneer, Tricog Health, has announced an ambitious goal to perform 100 million, or 10 crore, cardiac screenings by the year 2030. This target underscores the company's commitment to significantly enhance preventive heart care, both within India and globally. The firm, founded in 2014, has already made substantial progress, having screened over 41 million patients for various heart conditions.
Under the leadership of CEO Dr. Charit Bhograj, Tricog Health has established itself as a frontrunner in utilising advanced technology for early disease detection. The core of its diagnostic approach lies in its proprietary AI-enabled Electrocardiogram (ECG) devices. These sophisticated devices are designed to quickly and accurately capture cardiac data, which is then analysed by artificial intelligence algorithms to identify potential anomalies.
Crucially, Tricog Health's methodology doesn't solely rely on AI. It integrates a vital human element by complementing AI analysis with reviews from a team of specialist doctors. This hybrid approach ensures a high degree of accuracy and reliability in diagnoses, combining the speed and efficiency of AI with the nuanced expertise of medical professionals. This dual-layered system is pivotal in ensuring that potential heart conditions are identified with precision.
The primary objective of Tricog Health's technology and expansive screening efforts is to address the critical challenges of diagnosis delays and improve the early detection of cardiovascular diseases (CVDs). Early diagnosis is paramount in managing heart conditions effectively, as it allows for timely intervention, lifestyle modifications, and treatment plans that can significantly improve patient outcomes and quality of life. By reducing the time taken for a diagnosis, Tricog aims to bridge a crucial gap in healthcare delivery, particularly in regions with limited access to specialised cardiology services.
Tricog Health's operations span across several states within India, demonstrating a strong focus on enhancing domestic healthcare infrastructure. Beyond national borders, the company has successfully extended its reach to 14 other countries, highlighting the global applicability and demand for its innovative cardiac screening solutions. This extensive footprint enables the firm to impact a diverse patient population, contributing to a broader public health benefit.
The target of 10 crore cardiac screenings by 2030 reflects a proactive strategy to combat the growing burden of heart-related ailments through accessible and technology-driven preventive care. It signals a future where advanced diagnostics are more readily available, empowering individuals to take informed steps towards maintaining their heart health.
This report is for informational purposes only and does not constitute medical or investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is Tricog Health's target for cardiac screenings?
Tricog Health aims to conduct 100 million (10 crore) cardiac screenings by the year 2030.
How does Tricog Health detect heart conditions?
The company uses advanced AI-enabled ECG devices combined with reviews by specialist doctors to identify heart conditions effectively.
Where does Tricog Health operate?
Tricog Health operates across several states in India and extends its services to 14 other countries globally.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Indian Pharma Needs Digital Push to Boost Innovation, Says Kiran Mazumdar-Shaw
Biocon Chairperson Kiran Mazumdar-Shaw highlighted that Indian pharmaceutical companies are too risk-averse, hindering innovation. She urged greater adoption of digital technology to accelerate drug development and move beyond a generics-focused industry.
Drug Regulator Seeks Answers on Unapproved Medicines in National Formulary of India
India's drug regulator, DCGI, has sought an explanation from the Indian Pharmacopoeia Commission (IPC) regarding the inclusion of several unapproved drugs in the latest edition of the National Formulary of India (NFI 2026). This discrepancy raises concerns about drug safety and official guidance for medical professionals, while stakeholders also note the unavailability of its online version.
Health Ministry Proposes New Curbs on Prescription Drug Ads by Retailers
The Union Health Ministry is moving to restrict how retailers and distributors advertise prescription medicines, requiring prior government approval for certain drugs. This proposed change extends existing rules that currently apply only to pharmaceutical manufacturers and targets medicines under Schedules H, H1, and X, which demand medical supervision.
Related Stories
Indian Pharma Needs Digital Push to Boost Innovation, Says Kiran Mazumdar-Shaw
Biocon Chairperson Kiran Mazumdar-Shaw highlighted that Indian pharmaceutical companies are too risk-averse, hindering innovation. She urged greater adoption of digital technology to accelerate drug development and move beyond a generics-focused industry.
Drug Regulator Seeks Answers on Unapproved Medicines in National Formulary of India
India's drug regulator, DCGI, has sought an explanation from the Indian Pharmacopoeia Commission (IPC) regarding the inclusion of several unapproved drugs in the latest edition of the National Formulary of India (NFI 2026). This discrepancy raises concerns about drug safety and official guidance for medical professionals, while stakeholders also note the unavailability of its online version.
Health Ministry Proposes New Curbs on Prescription Drug Ads by Retailers
The Union Health Ministry is moving to restrict how retailers and distributors advertise prescription medicines, requiring prior government approval for certain drugs. This proposed change extends existing rules that currently apply only to pharmaceutical manufacturers and targets medicines under Schedules H, H1, and X, which demand medical supervision.
BreakingEli Lilly to Launch Four New Weight-Loss Drugs, Sees Potential in Indian Biotech Despite Funding Lag
Pharmaceutical giant Eli Lilly, driven by the success of Mounjaro and Zepbound, aims to launch up to four new weight-loss products in the coming years. The company acknowledges India's strong biotechnology talent and expertise, but highlights existing challenges in the research funding environment. Eli Lilly has expressed openness to forming partnerships with Indian biotech firms for future collaborations.